Amit Bar‐Or
Roche (Switzerland)
Affiliation Roche (Switzerland) Top Publications B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis (2008) – 2,454 citations Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis (2016) – 2,051 citations Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis (2016) – 1,923 citations Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis (2012) – 1,741 ... <a title="Amit Bar‐Or" class="read-more" href="https://journalsworld.com/researchers/amit-bar%e2%80%90or/" aria-label="Read more about Amit Bar‐Or">Read more</a>
Read biography ↓Biography, research & contributions
Affiliation
Roche (Switzerland)
Top Publications
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis (2008) - 2,454 citations
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis (2016) - 2,051 citations
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis (2016) - 1,923 citations
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis (2012) - 1,741 citations
- Multiple sclerosis (2018) - 1,468 citations
At a glance
- Full name
- Amit Bar‐Or
- ORCID
- 0000-0001-7179-0335
- OpenAlex ID
- https://openalex.org/A5077310868
Research interests
- Multiple Sclerosis Research Studies, Psoriasis: Treatment and Pathogenesis, T-cell and B-cell Immunology, Polyomavirus and related diseases, Chronic Lymphocytic Leukemia Research
Research topics
Education
Not yet documented in this profile.
Selected research & further reading
A curated reading list, not a ranking by citation count. References use DOI metadata, matching public scholarly records or authoritative lecture sources.
See the source-linked reading and original works in the research guide above.
Citation & publication trends
Annual counts are not yet available from a verified author record. Explore the research guide above for the work itself; publication and citation totals depend on database coverage.
Source: OpenAlex · Retrieved 2026-10-08. Metrics are database-specific and are not a scientific ranking.
Most-cited linked publications
Publications matched across ORCID and OpenAlex. Citation counts are source-specific.
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis ↗2008 · New England Journal of Medicine2,454OpenAlex citations
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis ↗2016 · New England Journal of Medicine2,051OpenAlex citations
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis ↗2016 · New England Journal of Medicine1,923OpenAlex citations
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis ↗2012 · New England Journal of Medicine1,741OpenAlex citations
- Multiple sclerosis ↗2018 · Nature Reviews Disease Primers1,468OpenAlex citations
Recent linked publications
Publications matched across ORCID and OpenAlex. Citation counts are source-specific.
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis ↗2008 · New England Journal of Medicine
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis ↗2016 · New England Journal of Medicine
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis ↗2016 · New England Journal of Medicine
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis ↗2012 · New England Journal of Medicine
- Multiple sclerosis ↗2018 · Nature Reviews Disease Primers
Journals published in
No verified record links added yet.
Related publishers
No verified record links added yet.
Institutions
Current verified institution
No verified record links added yet.
Previous institutions
No verified record links added yet.
Awards & honors
Not yet documented in this profile.
Career timeline
Not yet documented in this profile.
Co-authors
No verified record links added yet.
Education & career institution links
No verified record links added yet.
Claim & manage this profile
Are you this researcher? Sign in, provide identity evidence, and request administrator approval. Editing becomes available only after approval.
Sign in to claim this profileSources & data information
Editorial review: 2026-10-08 · Last data update: 2026-10-08 00:18:09
Unknown values are left blank. Linked publications may be a subset of total works. Identity verification, data retrieval and profile ownership are separate checks.